AB Science S.A. (EPA:AB)

Market Cap	93.04M
Revenue (ttm)	1.08M
Net Income (ttm)	-6.04M
Shares Out	65.25M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,259
Average Volume	56,583
Open	1.496
Previous Close	1.426
Day's Range	1.442 - 1.498
52-Week Range	0.770 - 2.340
Beta	1.69
RSI	62.32
Earnings Date	Apr 30, 2025

About AB Science

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 57
• Stock Exchange: Euronext Paris
• Ticker Symbol: AB

Financial Performance

In 2023, AB Science's revenue was 970,000, an increase of 1.25% compared to the previous year's 958,000. Losses were -11.99 million, -11.97% less than in 2022.